Suppression of Bone Resorption in Early Postmenopausal Women by Intranasal Salmon Calcitonin in Relation to Dosage and Basal Bone Turnover

1998 ◽  
Vol 62 (5) ◽  
pp. 379-382 ◽  
Author(s):  
B. Ongphiphadhanakul ◽  
N. Piaseu ◽  
L. Chailurkit ◽  
R. Rajatanavin
Keyword(s):  
Bone Resorption ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Salmon Calcitonin ◽  
Basal Bone ◽  
Early Postmenopausal Women

Calcium Supplementation Suppresses Bone Resorption in Early Postmenopausal Women

1998 ◽  
Vol 62 (1) ◽  
pp. 8-12 ◽  
Author(s):  
F. Scopacasa ◽  
M. Horowitz ◽  
J. M. Wishart ◽  
A. G. Need ◽  
H. A. Morris ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Postmenopausal Women ◽  
Calcium Supplementation ◽  
Early Postmenopausal Women

1-α-Hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women

Bone ◽  
1997 ◽  
Vol 20 (6) ◽  
pp. 557-562 ◽  
Author(s):  
J.-T. Chen ◽  
M. Shiraki ◽  
K. Hasumi ◽  
N. Tanaka ◽  
K. Katase ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Women ◽  
Early Postmenopausal Women

Effect of Risedronate on Osteocyte Viability and Bone Turnover in Paired Iliac Bone Biopsies from Early Postmenopausal Women

2010 ◽  
Vol 87 (5) ◽  
pp. 392-397 ◽  
Author(s):  
S. Qiu ◽  
R. J. Phipps ◽  
F. H. Ebetino ◽  
S. Palnitkar ◽  
D. Sudhaker Rao
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Women ◽  
Iliac Bone ◽  
Early Postmenopausal Women ◽  
Bone Biopsies

scholarly journals Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

2003 ◽  
Vol 111 (8) ◽  
pp. 1221-1230 ◽  
Author(s):  
Guitty Eghbali-Fatourechi ◽  
Sundeep Khosla ◽  
Arunik Sanyal ◽  
William J. Boyle ◽  
David L. Lacey ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Postmenopausal Women ◽  
Rank Ligand ◽  
Early Postmenopausal Women

Interaction between body mass index and bone turnover during aromatase inhibition: Evidence from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 560-560 ◽  
Author(s):  
E. McCloskey ◽  
R. Hannon ◽  
G. Lakner ◽  
G. Clack ◽  
A. Miyamoto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Bone Resorption ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Body Mass ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Baseline Bmi ◽  
High Bmi

560 Background: High body mass index (BMI) protects against postmenopausal osteoporotic fracture, mediated in part by higher endogenous levels of oestradiol. Third-generation aromatase inhibitors (AIs) show superior efficacy and tolerability than tamoxifen in the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. We examined the interactions between BMI and bone turnover during treatment with 3 aromatase inhibitors in the LEAP trial, an open, randomized, pharmacodynamic study in postmenopausal women. Methods: Healthy volunteers from the UK and Hungary with normal bone density and BMI between 18 and 34 kg/m2 were randomized to receive A (1 mg/day), L (2.5 mg/day), or E (25 mg/day) orally, once daily for 24 weeks. Effects on bone resorption (log transformed serum C-telopeptide crosslinks, CTX) and bone formation (bone alkaline phosphatase and propeptide of type I procollagen, PINP) were compared. Changes in biochemical markers of bone resorption and formation during treatment were all statistically inter- correlated (p<0.01) with no notable differences between the 3 agents studied, so that the groups were pooled for analysis. Spearman correlation coefficients and the p-values were computed. Results: A total of 90 participants were evaluable at baseline and at 24 weeks (29 A, 29 L, 32 E). As expected, baseline BMI correlated with pre-treatment circulating endogenous oestradiol (r=0.28, p=0.007) and both BMI and oestradiol negatively correlated with baseline serum CTX (r=-0.32, p=0.0025 and r=-0.35, p=0.0007 respectively) and PINP (r=-0.30, p=0.004 and r=-0.26, p=0.016 respectively). Baseline BMI and oestradiol were significantly correlated with the increase in serum CTX (r=0.26, p=0.015 and r=0.23, p=0.032 respectively) and BMI also correlated significantly with the increase in serum PINP (r=0.23, p=0.030). Conclusions: Steroidal and non-steroidal AIs increase bone turnover with the greatest increase in women with high BMI and higher oestradiol levels at baseline. As increased bone turnover is an independent risk factor for fracture, a high BMI may not confer a reduced fracture risk in the setting of AI use in early breast cancer. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document